Publications by authors named "Lea Sequier"
Treatment sequencing in inflammatory bowel disease: Towards clinical precision medicine.
Best Pract Res Clin Gastroenterol
August 2025
Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, raise ongoing challenges in clinical management due to their variable courses and impact on patient quality of life. The emergence of advanced therapies, from biologics to small molecules, has prompted the need for effective sequencing strategies to optimize patient outcomes. To this date, there is no algorithm for treatment sequencing and physicians must select the safest and most effective treatment according to each individual patient.
View Article and Find Full Text PDFBackground: The advent of advanced therapies in the recent years have improved outcomes for inflammatory bowel disease patients, but a significant subset of patients remains refractory to monotherapy. Advanced combination therapy, involving two biologic agents or a biologic combined with a small molecule drug, is emerging as a potential strategy to improve clinical remission and address extra-intestinal manifestations.
Methods: This narrative review summarizes current evidence on advanced combination therapy for inflammatory bowel disease, including mechanisms of action, clinical efficacy, safety considerations, and future perspectives.
Clinical experience of using biosimilars in Crohn's disease and their effectiveness.
Expert Opin Biol Ther
October 2024
Article Synopsis
- The approval of biosimilars for treating inflammatory bowel diseases (IBDs) helps address rising healthcare costs and improve treatment availability, particularly for Crohn's disease (CD).
- Since 2013, many biosimilars have been approved in Europe, with substantial clinical studies demonstrating their effectiveness in CD treatment across a diverse patient population.
- Experts recommend integrating biosimilars into standard clinical practice due to their proven efficacy and safety, as evidenced by significant increases in usage rates for infliximab and adalimumab in European countries.
Systematic review: Methotrexate-A poorly understood and underused medication in inflammatory bowel disease.
Aliment Pharmacol Ther
September 2024
Background: Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines.
Aims: To review the efficacy, safety, optimal dosing and delivery regimens of methotrexate in adults with IBD.
Methods: We conducted a systematic review of studies involving patients with IBD treated with methotrexate from inception to August 2023.